• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性硬化性胆管炎内镜治疗后黄疸消退和生存的预测因素。

Predictors of Jaundice Resolution and Survival After Endoscopic Treatment of Primary Sclerosing Cholangitis.

机构信息

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Department of Internal Medicine IV, University Hospital of Heidelberg, Heidelberg, Germany.

出版信息

Hepatol Commun. 2022 Apr;6(4):809-820. doi: 10.1002/hep4.1813. Epub 2021 Sep 1.

DOI:10.1002/hep4.1813
PMID:34558848
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8948596/
Abstract

The benefit of endoscopic retrograde cholangiopancreatography (ERCP) for the treatment of primary sclerosing cholangitis (PSC) remains controversial. To identify predictors of jaundice resolution after ERCP and whether resolution is associated with improved patient outcomes, we conducted a retrospective cohort study of 124 patients with jaundice and PSC. These patients underwent endoscopic biliary balloon dilation and/or stent placement at an American tertiary center, with validation in a separate cohort of 102 patients from European centers. Jaundice resolved after ERCP in 52% of patients. Median follow-up was 4.8 years. Independent predictors of jaundice resolution included older age (P = 0.048; odds ratio [OR], 1.03 for every 1-year increase), shorter duration of jaundice (P = 0.059; OR, 0.59 for every 1-year increase), lower Mayo Risk Score (MRS) (P = 0.025; OR, 0.58 for every 1-point increase), and extrahepatic location of the most advanced biliary stricture (P = 0.011; OR, 3.13). A logistic regression model predicted jaundice resolution with area under the receiver operator characteristic curve of 0.67 (95% confidence interval, 0.5-0.79) in the validation set. Independent predictors of death or transplant during follow-up included higher MRS at the time of ERCP (P < 0.0001; hazard ratio [HR], 2.33 for every 1-point increase), lower total serum bilirubin before ERCP (P = 0.031; HR, 0.91 for every 1 mg/dL increase), and persistence of jaundice after endoscopic therapy (P = 0.003; HR, 2.30). Conclusion: Resolution of jaundice after endoscopic treatment of biliary strictures is associated with longer transplant-free survival of patients with PSC. The likelihood of resolution is affected by demographic, hepatic, and biliary variables and can be predicted using noninvasive data. These findings may refine the use of ERCP in patients with jaundice with PSC.

摘要

内镜逆行胰胆管造影术(ERCP)治疗原发性硬化性胆管炎(PSC)的益处仍存在争议。为了确定 ERCP 后黄疸消退的预测因素,以及是否与患者预后改善相关,我们对 124 例黄疸合并 PSC 患者进行了回顾性队列研究。这些患者在美国一家三级中心接受了内镜胆道球囊扩张和/或支架置入,在来自欧洲中心的 102 例患者的另一队列中进行了验证。52%的患者 ERCP 后黄疸消退。中位随访时间为 4.8 年。黄疸消退的独立预测因素包括年龄较大(P=0.048;每增加 1 岁,优势比 [OR] 为 1.03)、黄疸持续时间较短(P=0.059;OR,每增加 1 年,为 0.59)、较低的 Mayo 风险评分(MRS)(P=0.025;OR,每增加 1 分,为 0.58)和最严重胆道狭窄的肝外位置(P=0.011;OR,每增加 1 分,为 3.13)。验证组中,逻辑回归模型预测黄疸消退的受试者工作特征曲线下面积为 0.67(95%置信区间,0.5-0.79)。随访期间死亡或移植的独立预测因素包括 ERCP 时更高的 MRS(P<0.0001;HR,每增加 1 分,为 2.33)、ERCP 前总血清胆红素较低(P=0.031;HR,每增加 1mg/dL,为 0.91)和内镜治疗后黄疸持续存在(P=0.003;HR,每增加 1 分,为 2.30)。结论:胆道狭窄内镜治疗后黄疸消退与 PSC 患者无移植生存时间延长相关。消退的可能性受人口统计学、肝脏和胆道变量的影响,可使用非侵入性数据进行预测。这些发现可能会改进 ERCP 在伴有黄疸的 PSC 患者中的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ba2/8948596/07ad1f4acf8f/HEP4-6-809-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ba2/8948596/32e65dbd88c8/HEP4-6-809-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ba2/8948596/30c302f42a87/HEP4-6-809-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ba2/8948596/39d574f44763/HEP4-6-809-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ba2/8948596/07ad1f4acf8f/HEP4-6-809-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ba2/8948596/32e65dbd88c8/HEP4-6-809-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ba2/8948596/30c302f42a87/HEP4-6-809-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ba2/8948596/39d574f44763/HEP4-6-809-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ba2/8948596/07ad1f4acf8f/HEP4-6-809-g001.jpg

相似文献

1
Predictors of Jaundice Resolution and Survival After Endoscopic Treatment of Primary Sclerosing Cholangitis.原发性硬化性胆管炎内镜治疗后黄疸消退和生存的预测因素。
Hepatol Commun. 2022 Apr;6(4):809-820. doi: 10.1002/hep4.1813. Epub 2021 Sep 1.
2
Predictors of successful clinical and laboratory outcomes in patients with primary sclerosing cholangitis undergoing endoscopic retrograde cholangiopancreatography.接受内镜逆行胰胆管造影术的原发性硬化性胆管炎患者临床及实验室检查结果成功的预测因素
Can J Gastroenterol. 2003 Apr;17(4):243-8. doi: 10.1155/2003/475603.
3
Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis.原发性硬化性胆管炎患者主狭窄计划性内镜扩张对结局的影响。
Gut. 2019 Dec;68(12):2170-2178. doi: 10.1136/gutjnl-2018-316801. Epub 2019 Mar 25.
4
Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis. Dutch PSC Study Group.原发性硬化性胆管炎患者内镜逆行胰胆管造影术的前瞻性风险评估。荷兰原发性硬化性胆管炎研究组。
Endoscopy. 2000 Oct;32(10):779-82. doi: 10.1055/s-2000-7708.
5
Comorbidities, sphincterotomy, and balloon dilation predict post-ERCP adverse events in PSC patients: operator experience is protective.合并症、括约肌切开术和气囊扩张术可预测 PSC 患者 ERCP 后的不良事件:术者经验具有保护作用。
Dig Dis Sci. 2011 Dec;56(12):3685-8. doi: 10.1007/s10620-011-1830-8. Epub 2011 Jul 26.
6
Clinical outcomes and reintervention after endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis in absence of cholangitis.原发性硬化性胆管炎患者在无胆管炎时行内镜逆行胰胆管造影术的临床结果和再次介入治疗。
Indian J Gastroenterol. 2024 Oct;43(5):1021-1029. doi: 10.1007/s12664-024-01630-1. Epub 2024 Jul 12.
7
Present and future role of endoscopic retrograde cholangiography in primary sclerosing cholangitis.内镜逆行胰胆管造影术在原发性硬化性胆管炎中的现在和未来作用。
Eur J Med Genet. 2021 Jun;64(6):104231. doi: 10.1016/j.ejmg.2021.104231. Epub 2021 Apr 24.
8
Three-months duration of fully-covered metal stent for refractory dominant extra-hepatic biliary stricture among primary sclerosing cholangitis patients: efficacy and safety.原发性硬化性胆管炎患者难治性肝外胆管主狭窄使用全覆膜金属支架三个月的疗效及安全性
Surg Endosc. 2022 Apr;36(4):2412-2417. doi: 10.1007/s00464-021-08522-x. Epub 2021 May 11.
9
No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis.原发性硬化性胆管炎患者主狭窄中支架与球囊扩张比较无优势。
Gastroenterology. 2018 Sep;155(3):752-759.e5. doi: 10.1053/j.gastro.2018.05.034. Epub 2018 May 24.
10
Primary sclerosing cholangitis increases the risk for pancreatitis after endoscopic retrograde cholangiopancreatography.原发性硬化性胆管炎会增加内镜逆行胰胆管造影术后胰腺炎的发病风险。
Liver Int. 2015 Jan;35(1):254-62. doi: 10.1111/liv.12640. Epub 2014 Jul 28.

引用本文的文献

1
Primary sclerosing cholangitis.原发性硬化性胆管炎
Nat Rev Dis Primers. 2025 Mar 13;11(1):17. doi: 10.1038/s41572-025-00600-x.
2
Yinzhihuang injection as adjuvant treatment for neonatal hyperbilirubinemia: a systematic review and meta-analysis of randomized clinical trials.茵栀黄注射液作为新生儿高胆红素血症的辅助治疗:一项随机临床试验的系统评价和荟萃分析
Front Pharmacol. 2024 Dec 5;15:1467325. doi: 10.3389/fphar.2024.1467325. eCollection 2024.
3
Primary sclerosing cholangitis-A long night's journey into day.原发性硬化性胆管炎——漫长黑夜后的黎明。

本文引用的文献

1
Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis.原发性硬化性胆管炎患者主狭窄计划性内镜扩张对结局的影响。
Gut. 2019 Dec;68(12):2170-2178. doi: 10.1136/gutjnl-2018-316801. Epub 2019 Mar 25.
2
Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis.原发性硬化性胆管炎患者行内镜胆道介入治疗的风险在有肝硬化和无肝硬化患者之间相似。
PLoS One. 2018 Aug 20;13(8):e0202686. doi: 10.1371/journal.pone.0202686. eCollection 2018.
3
No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis.
Clin Liver Dis (Hoboken). 2022 Dec 11;20(Suppl 1):21-32. doi: 10.1002/cld.1264. eCollection 2022 Nov.
4
Development and validation of a risk score for predicting clinical success after endobiliary stenting for malignant biliary obstruction.开发和验证一种用于预测恶性胆道梗阻内镜下胆道支架置入后临床成功的风险评分。
PLoS One. 2022 Aug 19;17(8):e0272918. doi: 10.1371/journal.pone.0272918. eCollection 2022.
原发性硬化性胆管炎患者主狭窄中支架与球囊扩张比较无优势。
Gastroenterology. 2018 Sep;155(3):752-759.e5. doi: 10.1053/j.gastro.2018.05.034. Epub 2018 May 24.
4
Performance of magnetic resonance elastography in primary sclerosing cholangitis.磁共振弹性成像在原发性硬化性胆管炎中的应用
J Gastroenterol Hepatol. 2016 Jun;31(6):1184-90. doi: 10.1111/jgh.13263.
5
Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience.原发性硬化性胆管炎患者的胆管癌和主要狭窄:25 年单中心经验。
Eur J Gastroenterol Hepatol. 2012 Sep;24(9):1051-8. doi: 10.1097/MEG.0b013e3283554bbf.
6
Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis.原发性硬化性胆管炎患者主胆管狭窄的诊断和治疗策略的分析综述。
HPB (Oxford). 2011 Feb;13(2):79-90. doi: 10.1111/j.1477-2574.2010.00268.x.
7
Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment.原发性硬化性胆管炎中优势狭窄的内镜扩张:长期治疗后的结果。
Gastrointest Endosc. 2010 Mar;71(3):527-34. doi: 10.1016/j.gie.2009.10.041.
8
A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis.内镜治疗症状性原发性硬化性胆管炎20年经验
J Clin Gastroenterol. 2008 Oct;42(9):1032-9. doi: 10.1097/MCG.0b013e3181646713.
9
Primary sclerosing cholangitis: the role of endoscopic therapy.原发性硬化性胆管炎:内镜治疗的作用
Semin Liver Dis. 2006 Feb;26(1):62-8. doi: 10.1055/s-2006-933564.
10
Dominant strictures in patients with primary sclerosing cholangitis.原发性硬化性胆管炎患者的主要狭窄
Am J Gastroenterol. 2004 Mar;99(3):502-8. doi: 10.1111/j.1572-0241.2004.04106.x.